Oyster Point Pharma, Inc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Oyster Point Pharma, Inc | OYST - NASDAQ |
$16.00-$18.00 | $16.00 | $16.50 | 5 million | 10/31/2019 |
| JP Morgan, Cowen, Piper Jaffray | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2019-10-04 Terms Added 2019-10-21 | ||||||
Oyster Point Pharma, Inc Quote & Chart - Click for current quote - OYST
IPO Boutique aggregates information on public companies and private companies, such as "OYST" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Oyster Point Pharma, Inc (adapted from Oyster Point Pharma, Inc prospectus):
They are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "OYST" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.